The ExoDx™ Prostate Test

Introducing the only exosome-based prostate cancer test delivering unique, actionable intelligence to help you decide if prostate biopsy is necessary, independent of PSA and other standard of care (SOC) information

Person

Assess prostate cancer risk

Leverages the power of exosomes to detect disease earlier in the progression of prostate cancer

What is the ExoDx Prostate Test?

Bottle

Precisely predictive, clinically convenient

Simple urine test, non-DRE, included in the NCCN guidelines to help guide your patient to biopsy decision

Discover the ExoDx Prostate Test Today!

Stethoscope

A new standard in prostate risk assessment

Clinical studies demonstrate the ExoDx Prostate test discriminates between high-grade and low-grade prostate cancer and benign disease

Publications and Abstracts

RNA DNA

A treasure trove of RNA, DNA and protein

Let us help you solve complex clinical and scientific challenges with liquid biopsy, exosome-based technology that is vastly superior to cfDNA and CTCs

What are Exosomes?

What's New

Meet the ExosomeDx Team

The ExoDx Prostate test is a simple urine test that detects three important genomic biomarkers that are markers of high-grade prostate cancer. Using this assessment, the physician can determine whether or not a patient should undergo a diagnostic biopsy.

Gaining access to molecular information from biofluids without needing direct access to the tissue itself will have far-reaching implications in patient management. While our diagnostics are initially focused on cancer, our exosome-based technology platform is potentially applicable to other diseases or medical conditions where molecular testing is beneficial, but where access to tissue is difficult or impossible. 

"To us, it's all about the patients and helping them through the process. This changes everything" - Dr. Johan Skog, Chief Scientific Officer:

Partner with Exosome Diagnostics

Meet Johan and Michael. "With what we know about exosomes, we are the perfect partners for helping pharma partners solve their research problems".

Johan is the Chief Scientific Officer at ExosomeDx and one of the world’s first scientists to discover exosomes. He immediately saw the opportunity of analyzing the RNA transcriptome profile to stratify patients as to how they respond to treatment. Michael is the Scientific Director and knew from a young age he wanted to be part of changing the course of cancer treatment.